Clinical trials · South Carolina
Prostate Cancer (Adenocarcinoma) clinical trials in South Carolina
We’re tracking 46 recruiting prostate cancer (adenocarcinoma) studies with a site in South Carolina — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in South Carolina
- NCT05011383RecruitingPhase 2
High-dose testosterone for prostate cancer with certain gene changes
This trial tests whether high doses of testosterone, a male hormone, can help slow or shrink prostate cancer that has stopped responding to usual hormone treatments, specifically in people whose tumors have changes in the ATM, CDK12, or CHEK2 genes.
Charleston, South CarolinaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Charleston, South CarolinaAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Charleston, South CarolinaAges 18 years+ - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Myrtle Beach, South CarolinaAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Myrtle Beach, South CarolinaAges 18 years+ - NCT07140900RecruitingPhase 1
Study of xaluritamig combined with hormone therapy for advanced prostate cancer
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
Myrtle Beach, South CarolinaAges 18 years+ - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Myrtle Beach, South CarolinaAges 18 years+ - NCT06629779RecruitingPhase 3
Study of Mevrometostat for Advanced Prostate Cancer
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Myrtle Beach, South CarolinaAges 18 years+ - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
Myrtle Beach, South CarolinaAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Myrtle Beach, South CarolinaAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Myrtle Beach, South CarolinaAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Myrtle Beach, South CarolinaAges 18 years+ - NCT05593497RecruitingPhase 2
Combination therapy before prostate surgery for high-risk prostate cancer
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
Charleston, South CarolinaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Myrtle Beach, South CarolinaAges 18 years+ - NCT07164443RecruitingPhase 3
Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
Charleston, South CarolinaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Myrtle Beach, South CarolinaAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Greenville, South CarolinaAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Charleston, South CarolinaAges 18–100 - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Myrtle Beach, South CarolinaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Myrtle Beach, South CarolinaAges 18–100 - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Charleston, South CarolinaAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Rock Hill, South CarolinaAges 18 years+
Where these studies are running in South Carolina
Institutions with a site for the recruiting prostate cancer (adenocarcinoma) studies listed above.
- Carolina Urologic Research Center · 10 studies
- Ralph H. Johnson VA Medical Center · 4 studies
- Research Site · 3 studies
- Medical University of South Carolina · 2 studies
- South Texas Accelerated Research Therapeutics - Carolinas · 2 studies
- AUC Urologists, LLC
- Carolina Blood and Cancer Care Associates
- Exelixis Clinical Site #9
What taking part in a prostate cancer (adenocarcinoma) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Prostate Cancer (Adenocarcinoma) trials in other states
Common questions
- Are there prostate cancer (adenocarcinoma) clinical trials in South Carolina?
- Yes. We're currently tracking 46 recruiting prostate cancer (adenocarcinoma) studies with a site in South Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer (adenocarcinoma) study in South Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in South Carolina to take part?
- Not necessarily. These studies have a site in South Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer (adenocarcinoma) studies open in South Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.